Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Net Income towards Common Stockholders (2019 - 2026)

C4 Therapeutics has reported Net Income towards Common Stockholders over the past 8 years, most recently at -$25.1 million for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders rose 4.53% year-over-year to -$25.1 million; the TTM value through Mar 2026 reached -$103.7 million, changed 0.39%, while the annual FY2025 figure was -$105.0 million, 0.31% changed from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was -$25.1 million at C4 Therapeutics, down from -$20.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$17.7 million in Q2 2024 and troughed at -$37.2 million in Q4 2022.
  • A 5-year average of -$29.1 million and a median of -$28.4 million in 2024 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 137.48% in 2022 and later soared 50.68% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$37.2 million in 2022, then grew by 6.53% to -$34.8 million in 2023, then grew by 0.53% to -$34.6 million in 2024, then surged by 41.1% to -$20.4 million in 2025, then decreased by 23.39% to -$25.1 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for CCCC at -$25.1 million in Q1 2026, -$20.4 million in Q4 2025, and -$32.2 million in Q3 2025.